The question is not really which product is “better.” It is whether you understand the clinical differences well enough to choose deliberately rather than by default.
Both Botox (onabotulinumtoxinA, Allergan/AbbVie) and Azzalure (abobotulinumtoxinA, Galderma) are licensed botulinum toxin type A products for upper face indications in the UK. Both are well-evidenced. Both carry excellent safety profiles in trained hands. But they are not interchangeable, and treating them as if they are is one of the most common sources of variable outcomes in clinical practice.
This piece is aimed at practitioners who already know how toxin works and want a sharper framework for deciding which product to use, and when.
The Formulation Difference Matters More Than You Think
Botox and Azzalure both contain botulinum toxin type A as their active component, but they are formulated differently, and those formulation differences have real clinical consequences. Botox uses onabotulinumtoxinA, complexed with haemagglutinin and non-haemagglutinin proteins. Azzalure uses abobotulinumtoxinA, a distinct strain with a different protein complex and molecular weight.
These differences affect three things that matter clinically: diffusion radius, onset speed, and the unit conversion you need to apply when switching between products or combining treatments.
Key point
Units are not interchangeable. One unit of Botox is not equivalent to one unit of Azzalure. The widely accepted conversion ratio is 1 unit Botox to approximately 2.5 to 3 units Azzalure, though individual patient response and clinical context should inform your specific dosing decisions.
Getting this wrong is one of the most commonly reported causes of under-treatment or unintended spread when practitioners switch products. If your clinic is transitioning from one to the other, or you are picking up a patient who has been treated elsewhere with a different toxin, factoring in this conversion is not optional.
Diffusion Profile: The Clinical Trade-Off
Azzalure has a broader diffusion radius than Botox. This is not a flaw; it is simply a characteristic that requires you to adjust your approach depending on the treatment area and the outcome you are aiming for.
In larger muscle groups, such as the frontalis or the bulk of the orbicularis oculi, wider diffusion can work in your favour. It can reduce the number of injection points needed and produce a more even result across the treated zone. Some practitioners find it particularly effective in patients with strong corrugator complex activity where they want to ensure thorough coverage without peppering the area.
In areas where precision is critical, however, broader diffusion introduces risk. Periorbital work, lower face treatments, lip lines, and anything close to the levator palpebrae superioris calls for a more contained spread. This is where Botox’s tighter diffusion profile gives you greater control. If you are working with less experienced injectors in your team, the relative predictability of Botox in these areas is worth factoring into your product choices.
Onset and Longevity: What to Tell Patients
Azzalure typically shows earlier onset, with many patients reporting visible relaxation within two to five days. Botox tends to take five to ten days to reach peak effect. This is worth communicating clearly at consultation, because patients who have switched products can otherwise interpret the quicker (or slower) response as either a more effective or a less effective treatment.
On longevity, the evidence and clinical experience broadly favour Azzalure for slightly longer duration, though this is far from universal. Patients with strong, frequently used muscles, high metabolism, or a history of toxin resistance tend to metabolise both products similarly. The reported longevity advantage for Azzalure is more consistent in patients who are naive to treatment or who have lower baseline muscle activity.
It is also worth acknowledging that duration data in published studies varies considerably depending on assessment method, injection area, and patient population. Treat the figures above as useful clinical approximations rather than guarantees.
Popularity and Prescribing Trends in the UK
Botox retains the strongest name recognition among patients, and this has a practical implication for how you frame consultations. Many patients will arrive requesting “Botox” as a generic term when they simply mean toxin treatment. This gives you the opportunity to guide them towards the most clinically appropriate product without feeling as though you are overriding their preference.
Within the practitioner community, the split is considerably more even than public perception suggests. Azzalure has built a strong following, particularly among practitioners who trained in Europe or who regularly attend Galderma-led clinical education. Its popularity has grown steadily since it entered the UK market, and in some clinical circles it is now the preferred first-line product for the upper face.
The UK aesthetics regulatory landscape has also shifted meaningfully in recent years. The implementation of the Health and Care Act 2022 provisions has tightened the requirements around who can administer prescription-only aesthetics treatments, which in practical terms should already be shaping how toxin is prescribed and delegated in your clinic. Whichever product you use, the prescribing and oversight framework is the same.
Price, Supply, and Business Considerations
From a practice economics standpoint, Azzalure is often slightly more cost-effective to purchase wholesale than Botox, though this varies by supplier and volume. The unit cost difference is not dramatic, but across a high-volume clinic it is worth factoring into your overall cost-per-treatment calculation.
Shelf life and wastage are also relevant. Azzalure’s 125-unit vials suit practices that are doing a reasonable volume of upper face toxin in a single session. Botox’s 50-unit vials offer more flexibility if you are treating fewer patients per clinic day and want to minimise wastage. Both products, once reconstituted, should be used within four hours (or per your local policy), and proper cold chain management is essential for both.
If you are considering expanding your offering or training an associate, there is a reasonable argument for standardising on one product initially rather than managing two different unit systems, dilution protocols, and patient documentation frameworks simultaneously. Proficiency with one product, properly applied, consistently outperforms inconsistent switching between two.
Looking for a legitimate and verified place to purchase Azzalure and Botox? We’ve got you covered!
If you’d like to learn more, head over to our official TikTok account and listen to Ash Simpson-Davies (BSc, MSc, RN), co-founder of Faces Consent, as he talks about Azzalure and Botox.